Dr. Spiess discusses differences in MTAP incidence and deletion across various tumors
March 4th 2022“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.
The value of hereditary cancer risk assessment in the community urology practice setting
March 3rd 2022At the 2022 ASCO Genitourinary Cancers Symposium, Neal D. Shore, MD, FACS, presented findings of the prospective study, "Hereditary cancer risk assessment in the community urology practice setting."
Dr. Burnett on Viagra: “This transformed the field in a significant way”
March 2nd 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Arthur L. Burnett, MD, MBA, FACS, discusses how sildenafil citrate (Viagra) has been an integral part of erectile dysfunction management for decades.
Dr. Shore on phase 3 ARASENS trial: “This is undoubtedly game-changing”
March 1st 2022“If you're going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.
Intermittent catheterization: From medical procedure to patient-controlled process
February 23rd 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, John Stoffel, MD, discusses the development of clean intermittent catheterization and how it has improved the care of patients with urologic conditions.
Lack of guidelines creates high rates of missed Lynch syndrome diagnosis in UTUC
February 22nd 2022“We found that while the NCCN guideline for Lynch syndrome is highly specific in identifying patients with Lynch syndrome, it missed about 50% of patients with upper tract cancer who had Lynch syndrome,” says Hong Truong, MD.